<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615754</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-232-19</org_study_id>
    <nct_id>NCT04615754</nct_id>
  </id_info>
  <brief_title>Ketones for Pulmonary Hypertension - Effects on Hemodynamics</brief_title>
  <acronym>KEPAH</acronym>
  <official_title>Ketone Administration in Patients With Pulmonary Hypertension - Effects on Hemodynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present study, patients with idiopathic pulmonary hypertension (IPAH) and chronic&#xD;
      thromboembolic pulmonary hypertenion will be investigated in a randomized cross-over design&#xD;
      with ketone infusions and placebo. Invasive and non-invasive hemodynamics will be evaluated&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary hypertension (PH) is a debilitating disease that affects both the pulmonary&#xD;
      vasculature and the heart. It is associated with increased mortality and hospitalization and&#xD;
      impairs daily life for the affected patients. Despite substantial advances in treatment&#xD;
      within the past decade the prognosis remains poor with an 1-year mortality of more than 10%.1&#xD;
      The pathophysiology of PH is multifactorial and can be caused by left sided cardiac disease,&#xD;
      pulmonary pathophysiological changes in the pulmonary vessels, respiratory diseases and&#xD;
      pulmonary embolism.The treatment is targeted at the underlying cause. Hence, left sided heart&#xD;
      disease is treated with anticongestive medications4 and respiratory disease by pulmonary&#xD;
      medications. However, pulmonary vascular diseases such as chronic thromboembolic pulmonary&#xD;
      hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH) are treated with&#xD;
      pulmonary endarterectomy and vasodilators targeting the pulmonary vasculature, respectively.&#xD;
      However, not all patients have an optimal pulmonary hemodynamic response on treatment. If&#xD;
      patients are left with persistent pulmonary hypertension the disease may progress further and&#xD;
      cause right heart failure which worsens the prognosis.&#xD;
&#xD;
      Data from a recent study conducted at the investigator's institution demonstrated 40%&#xD;
      increase in cardiac output during infusion of the ketone body 3-hydroxybutyrate (3-OHB).&#xD;
      Intriguingly, this was associated with an increase in RV function and a decrease in the&#xD;
      pulmonary vascular resistance of approximately 20%.&#xD;
&#xD;
      In the present study, 10 patients with IPAH and 10 patients with CETPH will be subjected to&#xD;
      placebo and 3-OHB infusion in a randomized cross-over design. Each of the infusions will be&#xD;
      given for 2.5 hours and cross-over will be carried out on the same day. Echocardiography and&#xD;
      right sided heart catheterization will be applied and blood will be sampled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized cross-over I.e. Ketone infusion is compared to saline infusion in a randomised cross-ove design.&#xD;
(Ketones are considered dietary supplement as glucose or lipids)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>The participant and the endpoint-assessor will be masked to intevention</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac output (L/min</measure>
    <time_frame>changes during the infusion for 2.5 hours compared to 2.5 hours of Saline infusion</time_frame>
    <description>Measured by Swan-Ganz monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mixed venous saturation (%)</measure>
    <time_frame>changes during the infusion for 2.5 hours compared to 2.5 hours of Saline infusion</time_frame>
    <description>Hemodynamics - Swan Ganz monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systemic blood pressure (mmHg)</measure>
    <time_frame>changes during the infusion for 2.5 hours compared to 2.5 hours of Saline infusion</time_frame>
    <description>Hemodynamics - non-invasive blood pressure measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary capillary pressure (mmHg)</measure>
    <time_frame>changes during the infusion for 2.5 hours compared to 2.5 hours of Saline infusion</time_frame>
    <description>Hemodynamics - Swan Ganz monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary pressure (mmHg)</measure>
    <time_frame>changes during the infusion for 2.5 hours compared to 2.5 hours of Saline infusion</time_frame>
    <description>Hemodynamics - Swan Ganz monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TAPSE (mm)</measure>
    <time_frame>changes during the infusion for 2.5 hours compared to 2.5 hours of Saline infusion</time_frame>
    <description>Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RV strain (%)</measure>
    <time_frame>changes during the infusion for 2.5 hours compared to 2.5 hours of Saline infusion</time_frame>
    <description>Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV strain (%)</measure>
    <time_frame>changes during the infusion for 2.5 hours compared to 2.5 hours of Saline infusion</time_frame>
    <description>Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systolic tricuspid plane velocity (cm/sec)</measure>
    <time_frame>changes during the infusion for 2.5 hours compared to 2.5 hours of Saline infusion</time_frame>
    <description>Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction (%)</measure>
    <time_frame>changes during the infusion for 2.5 hours compared to 2.5 hours of Saline infusion</time_frame>
    <description>Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Prostaglandines (pmol/L)</measure>
    <time_frame>changes during the infusion for 2.5 hours compared to 2.5 hours of Saline infusion</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH</measure>
    <time_frame>changes during the infusion for 2.5 hours compared to 2.5 hours of Saline infusion</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sodium (mM)</measure>
    <time_frame>changes during the infusion for 2.5 hours compared to 2.5 hours of Saline infusion</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>potassium (mM)</measure>
    <time_frame>changes during the infusion for 2.5 hours compared to 2.5 hours of Saline infusion</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lactate (mM)</measure>
    <time_frame>changes during the infusion for 2.5 hours compared to 2.5 hours of Saline infusion</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Ketonemia</condition>
  <arm_group>
    <arm_group_label>3-OHB vs Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-OHB will be infused for 2.5 hours in IPAH (n=5) and CETPH (n=5) patients- 6 in each group is recruited for taking drop-out into account</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline vs 3-OHB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saline will be infused for 2.5 hours in IPAH (n=5) and CETPH (n=5) patients- 6 in each group is recruited for taking drop-out into account</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hyperketonemia - use of ketone (3-OHB) infusion</intervention_name>
    <description>The effect of intravenous ketone supplement</description>
    <arm_group_label>3-OHB vs Saline</arm_group_label>
    <arm_group_label>Saline vs 3-OHB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo - use of saline infusion</intervention_name>
    <description>Saline is infused as an comparator</description>
    <arm_group_label>3-OHB vs Saline</arm_group_label>
    <arm_group_label>Saline vs 3-OHB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Persistent pulmonary hypertension (defined as PVR &gt; 3 WU, pulmonary capillary wedge&#xD;
             pressure (PCWP) &lt; 15 mmHG, mean pulmonary arterial pressure (mPAP) ≥25 mmHg) on the&#xD;
             most resent right heart catheterization.&#xD;
&#xD;
          -  Preserved left ventricular ejection fraction (&lt;50%) on most recent echocardiography&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other Significant pulmonary, mitral or aortic valve disease&#xD;
&#xD;
          -  Other disease or treatment making subject unsuitable for study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roni R Nielsen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Cardiology, Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roni R Nielsen, MD PhD</last_name>
    <phone>0045 5121 9363</phone>
    <email>roni.r.nielsen@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Søren MellemKjaer, MD PhD</last_name>
    <email>soren.mellemkjaer@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of cardiology, Aarhus University hospital Skejby,</name>
      <address>
        <city>Aarhus</city>
        <state>Region Midjylland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roni R Nielsen, MD</last_name>
      <phone>0045 5121 9363</phone>
      <email>roni.r.nielse@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Roni R Nielsen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Right sided heart catheterization</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>Hemodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ketosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

